Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
02/15/19 6:04 PM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Feb 13 2019
Summary ToggleAdverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference
- Feb 11 2019
Summary ToggleAdverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
- Jan 6 2019
Summary ToggleAdverum Biotechnologies Provides 2019 Outlook
- Dec 20 2018
Summary ToggleAdverum to Present at the 37th Annual J.P. Morgan Healthcare Conference